Clinical trial
Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca
NCT00349466 · Can-Fite BioPharma, Industry · Completed
Key facts
| NCT number | NCT00349466 |
|---|---|
| Title | Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca |
| Official title | A Phase 2, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Keratoconjunctivitis Sicca |
| Lead sponsor | Can-Fite BioPharma, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Keratoconjunctivitis Sicca |
| Intervention type | Drug |
| Interventions | CF101, Placebo |
| Enrollment | 80 |
| Start date | Jan 1, 2007 |
| Primary completion | May 1, 2009 |
| Completion | May 1, 2009 |
| First posted | Jul 7, 2006 |
| Last update posted | May 9, 2022 |
| Countries | Israel |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: